Dual Trigger with Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Improves Live Birth Rate for Women with Expected Normal Ovarian Response in Gonadotropin Releasing Hormone Antagonist Cycles: Retrospective Study

Objective: To evaluate and compare cycle outcomes following triggering final oocyte maturation with dual trigger of concomitant gonadotropin-releasing hormone (GnRH) agonist human chorionic gonadotropin (hCG) administration versus hCG alone for women expected normal ovarian response that underwent antagonist cycles intracytoplasmic sperm injection (ICSI). Material Methods: Women GnRH ICSI between January 2010 April 2020 were evaluated in this retrospective cohort study. A total 2,443 patients included. Dual was used 637 whereas 1,806 women. Cycles assigned to study group are taken as controls. Results: Number retrieved oocytes (14.08±3.58 vs. 13.15±3.61), number metaphase 2 (9.77±3.08 8.06±3.14), fertilization rate (0.75±0.19 0.69±0.19), implantation (0.43±0.48 0.35±0.50) clinical pregnancy (49.9% 40.6%) significantly higher comparison group. Higher good quality embryos obtained (85.7% 76.3%). Live birth increased only (45.1% 36.7%). Multivariate logistic regression analysis showed is a significant factor predicting live deliveries (odds ratio 1.426, 95% confidence interval 1.185-1.716). Conclusion: Dual-triggering appears improve embryo quality, increase rates, rates cycles.